{
  "id": 5464638,
  "title": "Earnings call transcript: PYC Therapeutics posts Q3 2026 EPS beat as trial data lifts outlook",
  "url": "https://urgent.news/2026/09/04/earnings-call-transcript-pyc-therapeutics-posts-q3-2026-eps-beat-as",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T01:18:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-pyc-therapeutics-posts-q3-2026-eps-beat-as-trial-data-lifts-outlook-93CH-4888746"
  },
  "original_language": "en",
  "account": "PYC Therapeutics announced earnings for Q3 2026, posting an EPS of -$0.0233, which greatly surpassed the expected loss of -$7.60. The company's revenue reached $28.64 million, though no comparison revenue was provided. The management emphasized the company's progress in clinical development rather than financial performance during the Q3 investor webinar.\n\nPYC Therapeutics is entering a critical period of clinical development, having reported an adjusted quarterly loss that was significantly smaller than expected. The company has outlined a series of human data readouts through 2027, marking its transition from an early-stage research company to a late-stage clinical development group.\n\nThe lead program, PYC-003 for autosomal dominant polycystic kidney disease (ADPKD), is moving through Phase I-B with 13 of 24 patients enrolled. Management highlighted the company's balance sheet strength, stating that it has enough capital to fund development through multiple late-stage programs. The company is preparing for potential U.S. listing steps and is entering a key window for human safety and efficacy data.\n\nAmong the other programs, PYC-001 for autosomal dominant optic atrophy and PYC-002 for Phelan-McDermid syndrome showed progress. Management also discussed the possibility of expanding the kidney program's patient cohort and extending the data set to provide a 24-month period. The company's approach to the kidney program is considered more specific, with a clean safety profile and lower doses compared to some rivals.\n\nPYC Therapeutics' stock rose 2.65% in after-hours trading to $2.32 after the earnings call, indicating a positive market response to the company's clinical update and balance sheet comments. The stock later traded at $2.565, close to the top of its 52-week range of $0.848 to $2.62. The positive price action suggests investors are encouraged by the company's clinical milestones and financial position.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Zscaler beats Q4 2026 estimates as AI demand lifts outlook",
        "url": "https://urgent.news/2026/09/03/earnings-call-transcript-zscaler-beats-q4-2026-estimates-as-ai-demand",
        "published": "2026-09-03T21:44:59.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}